Journal of Clinical Endocrinology & Metabolism, Vol 76, 711-714, Copyright © 1993 by Endocrine Society

ARTICLES

Gonadotropin-releasing hormone agonist-induced differences in granulosa cell cycle kinetics are associated with alterations in follicular fluid mullerian-inhibiting substance and androgen content

DB Seifer, DT MacLaughlin, AS Penzias, HR Behrman, L Asmundson, PK Donahoe, RV Haning Jr and SD Flynn
Division of Reproductive Endocrinology, Women and Infants Hospital, Brown University School of Medicine, Providence, Rhode Island 02905.

We have previously shown that the proliferative index (PI), as determined by flow cytometry of luteinized granulosa cells obtained at oocyte retrieval, is greater in ovulation induction regimens which include the GnRH analog (GnRH-a) leuprolide acetate than those using human menopausal gonadotropin (hMG) only. Specific growth factors or intrafollicular hormones may contribute to this leuprolide acetate- induced difference in cell cycle kinetics. We examined whether differences in the PI of these granulosa cells are associated with the alterations of follicular fluid content of Mullerian-inhibiting substance (MIS) and other intrafollicular hormones including FSH, estradiol, progesterone, androstenedione, and testosterone. The control group consisted of follicular fluid obtained from 18 follicles from 4 women receiving hMG alone. The GnRH-a treated group consisted of follicular fluids obtained from 55 follicles aspirated from 18 women receiving GnRH-a in addition to hMG. One-way analysis of variance using log-transformed data and expressed as geometric means with 95% confidence intervals, demonstrated that the follicles from the control group had a significant 14-fold higher concentration of 2.46 ng/mL MIS, 95% CI (1.8-4.8) vs. 0.18 ng/mL, 95% CI (0.13-0.24) P < 0.0005, a 3- fold higher concentration of 17.55 nmol/L androstenedione, 95% CI (14.6- 20.9) vs. 5.76 nmol/L, 95% CI (3.1-10.5) P < 0.02, and a 1.5-fold higher concentration of 29.43 nmol/L testosterone 95% CI (22.5-38.14) vs. 19.3 nmol/L, 95% of CI (11.1-33.9) P < 0.01 than GnRH-a treated follicles, although the PI value in controls was half that of the GnRH- a group. These data demonstrate that GnRH-a induced differences in granulosa cell cycle kinetics are associated with alterations of MIS and androgen intrafollicular fluid content and suggest that MIS may be a mitotic inhibitor of human granulosa cells.

This article has been cited by other articles:

				D. Monniaux, N. d. Clemente, J.-L. Touze, C. Belville, C. Rico, M. Bontoux, J.-Y. Picard, and S. Fabre Intrafollicular Steroids and Anti-Mullerian Hormone During Normal and Cystic Ovarian Follicular Development in the Cow Biol Reprod, August 1, 2008; 79(2): 387 - 396. [Abstract] [Full Text] [PDF]

				A. L. Marca and A. Volpe The Anti-Mullerian hormone and ovarian cancer Hum. Reprod. Update, May 1, 2007; 13(3): 265 - 273. [Abstract] [Full Text] [PDF]

				D. B. Seifer, D. T. MacLaughlin, and H. S. Cuckle Serum mullerian-inhibiting substance in Down's syndrome pregnancies Hum. Reprod., April 1, 2007; 22(4): 1017 - 1020. [Abstract] [Full Text] [PDF]

				C. Y. Andersen and A. G. Byskov Estradiol and Regulation of Anti-Mullerian Hormone, Inhibin-A, and Inhibin-B Secretion: Analysis of Small Antral and Preovulatory Human Follicles' Fluid J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4064 - 4069. [Abstract] [Full Text] [PDF]

				R. Fanchin, D. H. Mendez Lozano, N. Louafi, N. Achour-Frydman, R. Frydman, and J. Taieb Dynamics of serum anti-Mullerian hormone levels during the luteal phase of controlled ovarian hyperstimulation Hum. Reprod., March 1, 2005; 20(3): 747 - 751. [Abstract] [Full Text] [PDF]

				A. La Marca, S. Malmusi, S. Giulini, L. F. Tamaro, R. Orvieto, P. Levratti, and A. Volpe Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation Hum. Reprod., December 1, 2004; 19(12): 2738 - 2741. [Abstract] [Full Text] [PDF]

				A. J. Pask, D. J. Whitworth, C.-A. Mao, K.-J. Wei, N. Sankovic, J. A. M. Graves, G. Shaw, M. B. Renfree, and R. R. Behringer Marsupial Anti-Mullerian Hormone Gene Structure, Regulatory Elements, and Expression Biol Reprod, January 1, 2004; 70(1): 160 - 167. [Abstract] [Full Text] [PDF]

				A. L. L. Durlinger, M. J. G. Gruijters, P. Kramer, B. Karels, T. R. Kumar, M. M. Matzuk, U. M. Rose, F. H. de Jong, J. Th. J. Uilenbroek, J. A. Grootegoed, et al. Anti-Mullerian Hormone Attenuates the Effects of FSH on Follicle Development in the Mouse Ovary Endocrinology, November 1, 2001; 142(11): 4891 - 4899. [Abstract] [Full Text] [PDF]

				J. Teixeira, S. Maheswaran, and P. K. Donahoe Mullerian Inhibiting Substance: An Instructive Developmental Hormone with Diagnostic and Possible Therapeutic Applications Endocr. Rev., October 1, 2001; 22(5): 657 - 674. [Abstract] [Full Text] [PDF]

				A. L. L. Durlinger, P. Kramer, B. Karels, F. H. de Jong, J. Th. J. Uilenbroek, J. A. Grootegoed, and A. P. N. Themmen Control of Primordial Follicle Recruitment by Anti-Mullerian Hormone in the Mouse Ovary Endocrinology, December 1, 1999; 140(12): 5789 - 5796. [Abstract] [Full Text]

				J. Teixeira, E. Fynn-Thompson, A. H. Payne, and P. K. Donahoe Mullerian-Inhibiting Substance Regulates Androgen Synthesis at the Transcriptional Level Endocrinology, October 1, 1999; 140(10): 4732 - 4738. [Abstract] [Full Text]

				Y. Mishina, D. J. Whitworth, C. Racine, and R. R. Behringer High Specificity of Mullerian-Inhibiting Substance Signaling in Vivo Endocrinology, May 1, 1999; 140(5): 2084 - 2088. [Abstract] [Full Text]